|
Variate
|
Number of patients [cases (%)]
|
|---|
|
Total
|
220
|
|
Age (years)
| |
|
≤55
|
93 (42.3)
|
|
>55
|
127 (57.7)
|
|
Smoking status
| |
|
Never
|
95 (43.2)
|
|
Ever
|
125 (56.8)
|
|
Gender
| |
|
Male
|
165 (75.0)
|
|
Female
|
55 (25.0)
|
|
ECOG PS
| |
|
0–1
|
39 (17.7)
|
|
2
|
181 (82.3)
|
|
Histological type
| |
|
Adenocarcinoma
|
108 (49.1)
|
|
Squamous cell carcinoma
|
112 (50.9)
|
|
Stage
| |
|
I–II
|
8 (3.6)
|
|
III–IV
|
212 (96.4)
|
|
Platinum-based drug
| |
|
Cisplatin
|
37(16.8)
|
|
Carboplatin
|
183 (83.2)
|
|
Chemotherapy regimen
| |
|
Platinum-gemcitabine
|
112 (50.9)
|
|
Platinum-pemetrexed
|
68 (30.9)
|
|
Platinum-paclitaxel
|
23 (10.4)
|
|
Platinum-docetaxel
|
12 (5.5)
|
|
Platinum-navelbine
|
5 (2.3)
|
|
Severe toxicity
| |
|
Total
|
79 (35.9)
|
|
Hematologic toxicity
|
55 (25.0)
|
|
Gastrointestinal toxicity
|
31 (14.1)
|
-
ECOG Eastern Cooperative Oncology Group, PS performance status
